Diasorin SpAMIL:DIA +3.13%67 PB Ratio is 2.24 as of Jun. 25, 2026, which is 58% below its 10-year median of 5.29. GuruFocus rates MIL:DIA with a GF Score™ of 67/100 and a GF Value™ of €90.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 53.06% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Diasorin SpA's share price is €66.48. Diasorin SpA's Book Value per Share for the quarter that ended in Dec. 2025 was €29.74. Hence, Diasorin SpA's PB Ratio of today is 2.24.
The historical rank and industry rank for Diasorin SpA's PB Ratio or its related term are showing as below:
MIL:DIA'
s PB Ratio Range Over the Past 10 Years
Min: 1.94 Med: 5.29 Max: 12.42
Current: 2.24
During the past 13 years, Diasorin SpA's highest PB Ratio was 12.42. The lowest was 1.94. And the median was 5.29.
MIL:DIA's PB Ratio is ranked worse than 53.06% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs MIL:DIA: 2.24
During the past 12 months, Diasorin SpA's average Book Value Per Share Growth Rate was -10.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Diasorin SpA was 156.90% per year. The lowest was 1.70% per year. And the median was 17.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Diasorin SpA PB Ratio Related Terms
Diasorin SpA PB Ratio Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diasorin SpA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's PB Ratio distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Diasorin SpA's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Diasorin SpA (MIL:DIA) has a PB Ratio of 2.24 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diasorin SpA and its competitors. This is 58% below median its historical median of 5.29. Over the past decade, Diasorin SpA's PB Ratio has ranged from 1.94 to 12.42. According to the industry distribution chart, Diasorin SpA ranks #104 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 53.1%.
Is Diasorin SpA's PB Ratio too high?
Diasorin SpA's current PB Ratio of 2.24 is 58% below median its 10-year median of 5.29. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 12.42. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Diasorin SpA's value of 2.24 is 9.3% above this industry median. Based on the distribution chart, Diasorin SpA ranks #104 out of 196 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #104 out of 196 companies for PB Ratio. This places Diasorin SpA in the lower half of its industry. The industry median PB Ratio is 2.05. Diasorin SpA's value of 2.24 is 9.3% above this benchmark. Historically, Diasorin SpA's own PB Ratio has ranged from 1.94 to 12.42 over the past decade. While the company's 10-year median is 5.29 vs. the industry median of 2.05, Diasorin SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current PB Ratio of 2.24 is 9.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current PB Ratio is 2.24, which is 58% below median its own 10-year median of 5.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.07, compared to a current price of €66.48 — trading 26.2% below its estimated fair value. The current PB Ratio is 2.24, which is 58% below median its 10-year median of 5.29 and 9.3% above the Medical Diagnostics & Research industry median of 2.05. Diasorin SpA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current PB Ratio is 2.24 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €66.48 is trading 26.2% below its estimated GF Value™ of €90.07.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
PB Ratio: 2.24 (58% below median its 10-year median of 5.29)
GF Value™: €90.07 vs. price of €66.48 (26.2% below fair value)
Industry Position: 9.3% above the Medical Diagnostics & Research median (#104 of 196)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
67GF Score
Get the complete analysis for MIL:DIA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
